NIO Opleidingsdag Glomerulaire en intersititële nierziekten

NIO Opleidingsdag Hypertensie
Datum:
Tijd:
Locatie:
Dagvoorzitter:
28 november 2014
09.00-16.30 uur
Jaarbeurs Utrecht
P.J. Blankestijn
09.00-09.15
09.15-10.00
10.00-10.45
10.45-11.00
11.00-11.45
11.45-12.15
12.15-13.00
Welkom
Endocriene hypertensie
Hypertensive crise
KOFFIE
CKD als cardiovasculaire risicofactor
Renale hypertensie: pathofysiologie
LUNCH
P.J. Blankestijn
J Deinum
A.H. van den Meiracker
13.00-14.00
Renale denervatie: hoop of hype?
Interactieve discussie: wat is er gebeurd, wat
ging er fout en hoe nu verder?
THEE
Zwangerschapshypertensie
Water en zout
TOETS
P.J. Blankestijn
14.00-14.15
14.15-15.00
15.00-15.45
15.45-16.15
R. Gansevoort
P.J. Blankestijn
W. Visser
GJ Navis
P.J. Blankestijn
Leerdoelen:
De NIO heeft kennis van/kan:
1
a] de factoren die een rol spelen in de pathogenese,
b] de gevolgen van
c] de behandeldoelen en
d] behandelingsstrategieën van de verschillende vormen van hypertensie.
Refs
Funder JW, Carey RM, et al. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism:
An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 93: 3266-81.
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH,
Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine
society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42.
Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney
disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004; 65:1568-76.
Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of
the renin and sympathetic system? J Hypertens. 2009;27:1341-1349
de Beus E, de Jager R, Joles JA, Grassi G, Blankestijn PJ. Sympathetic activation secondary to chronic kidney
disease: therapeutic target for renal denervation? J Hypertens. 2014; 32: 1751-61
B.J.H. van den Born, J.J. Beutler, C.A.J.M. Gaillard, A. de Gooijer, A.H. van den Meiracker, A.A. Kroon. Dutch
guideline for the management of hypertensive crisis – 2010 revision. Neth J Med 2011, 6 9: 248-55
NIV richtlijn hypertensieve crisis. NIV website
Humalda JK, Navis GJ Dietary Sodium Restriction: a Neglected Therapeutic Opportunity in Chronic Kidney
Disease. Curr Opin Nephrol Hypertens 2014
Hung SC, Kuo KL, Peng CH et al. Volume overload correlates with cardiovascular risk factors in patients with
chronic kidney disease. Kidney Int. 2014;85:703-709
Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P,
Vanholder R, Wiecek A, Zoccali C, London GM; Board of the EURECA-m Working Group of ERA-EDTA.
Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;
383:1831-43.
De Groot C.J.M., Visser W, Steegers EAP. Zwangerschap en chronische hypertensie: risico’s en beleid. Ned
tijdschrift voor geneeskunde 2003;46,2281-4.
Hanff LM, Visser W, Vulto AG, Steegers EAP. Pharmacological management of severe pre-eclampsia. Eur
Clinics Obstet Gynaecol. 2006; 2: 9-17.
Up to date: clinical features, diagnosis, and long-term prognosis of preeclampsia, management of
hypertension in pregnancy, management of preeclampsia
HH Moussa et al. Management of hypertensive disorders in pregnancy. Women’s Health 2014; 10:385-404
P von Dadelszen et L. . Pre-eclampsia: An update. Curr Hypertens Resp 2014;16:1-14
T Podymow and Phyllis August. Update on the use of anthypertensive drugs in pregnancy. Hypertension
2008;51: 960-9
Up to date. Preeclampsia: clinical features and diagnosis
Up to date . Preeclampsia : Management and prognosis
Up to date . Preeclampsia: Pathogenesis

Download Report